Search

Chairs and Members

ChairUwe Platzbecker, University of Leipzig, Medical Faculty, Clinic and Polyclinic for Hematology, Cellular Therapy and Hemostaseology (Germany)

Co-chairLionel Adès, Hôpital Saint-Louis Paris, Hématologie Seniors (France)

SWG Steering Committee
Pierre Fenaux, Hôpital Saint-Louis, Hématologie Seniors, Paris (France)
Arjan van de Loosdrecht, Amsterdam UMC, Hematology (The…

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Chairs and members

Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia

Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany

SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more